Stay updated on VAX-24 Safety and Immunogenicity in Adults Clinical Trial

Sign up to get notified when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a modification in the dose levels of the 24-valent pneumococcal conjugate vaccine (VAX-24) being compared to Prevnar 20™ (PCV20) in adults aged 18 to 49 years in Phase 1, and in adults aged 50 to 64 years in Phase 2 of the clinical study.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:02.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying age ranges and health conditions required for inclusion in Phase 1 and Phase 2 of the study. Previously, no information was provided in this section.
    Difference
    29%
    Check dated 2024-05-22T21:02:44.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:28:59.000Z thumbnail image

Stay in the know with updates to VAX-24 Safety and Immunogenicity in Adults Clinical Trial

Enter your email address, and we'll notify you when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.